TG THERAPEUTICS ($TGTX) posted quarterly earnings results for Q4 2025 on Thursday, February 26th. The company reported earnings of $0.14 per share, missing estimates of $0.36 by $0.22. The company also reported revenue of $192,570,000, missing estimates of $196,057,647 by $-3,487,647.
You can see Quiver Quantitative's $TGTX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
TG THERAPEUTICS Insider Trading Activity
TG THERAPEUTICS insiders have traded $TGTX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $TGTX stock by insiders over the last 6 months:
- SAGAR LONIAL sold 20,852 shares for an estimated $672,268
- YANN ECHELARD sold 5,000 shares for an estimated $162,850
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
TG THERAPEUTICS Hedge Fund Activity
We have seen 178 institutional investors add shares of TG THERAPEUTICS stock to their portfolio, and 213 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CONGRESS ASSET MANAGEMENT CO added 1,922,410 shares (+inf%) to their portfolio in Q4 2025, for an estimated $57,307,042
- CLEARBRIDGE INVESTMENTS, LLC removed 1,196,442 shares (-25.8%) from their portfolio in Q4 2025, for an estimated $35,665,936
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 807,833 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $29,182,967
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 741,518 shares (-75.6%) from their portfolio in Q4 2025, for an estimated $22,104,651
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 705,419 shares (-18.3%) from their portfolio in Q4 2025, for an estimated $21,028,540
- BNP PARIBAS FINANCIAL MARKETS added 612,189 shares (+856.6%) to their portfolio in Q4 2025, for an estimated $18,249,354
- JUMP FINANCIAL, LLC removed 595,356 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $17,747,562
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
TG THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $TGTX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/06/2025
- B. Riley Securities issued a "Buy" rating on 09/17/2025
To track analyst ratings and price targets for TG THERAPEUTICS, check out Quiver Quantitative's $TGTX forecast page.
TG THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $TGTX recently. We have seen 5 analysts offer price targets for $TGTX in the last 6 months, with a median target of $49.0.
Here are some recent targets:
- Brian Cheng from JP Morgan set a target price of $46.0 on 02/02/2026
- Corinne Johnson from Goldman Sachs set a target price of $39.0 on 01/15/2026
- Emily Bodnar from HC Wainwright & Co. set a target price of $60.0 on 10/06/2025
- Mayank Mamtani from B. Riley Securities set a target price of $55.0 on 09/17/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
